• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MoCA 与 Mattis 痴呆评定量表-2 在帕金森病中的比较敏感性。

Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.

机构信息

Department of Psychological and Brain Sciences, Washington University, St. Louis, Missouri, USA.

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.

出版信息

Mov Disord. 2019 Feb;34(2):285-291. doi: 10.1002/mds.27575. Epub 2018 Dec 10.

DOI:10.1002/mds.27575
PMID:30776152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6532623/
Abstract

BACKGROUND

Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD.

METHODS

The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521).

RESULTS

The Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0% and 80.3%, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5% and 60.3%, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9% and 87.8%, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2%).

CONCLUSION

The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD. © 2018 International Parkinson and Movement Disorder Society.

摘要

背景

临床医生和研究人员通常使用全球认知评估来筛选损伤。目前尚无研究直接比较蒙特利尔认知评估和 Mattis 痴呆评定量表-2 在 PD 中的敏感性和特异性。本研究旨在确定蒙特利尔认知评估和 Mattis 痴呆评定量表-2 在 PD 中的相对敏感性和特异性。

方法

在训练和验证队列中进行蒙特利尔认知评估和 Mattis 痴呆评定量表-2。在训练队列(n=85)中确定最佳敏感性和特异性的认知障碍的截断值,并将其应用于独立验证队列(n=521)。

结果

蒙特利尔认知评估在训练和验证队列中始终具有较高的敏感性(分别为 90.0%和 80.3%),而 Mattis 痴呆评定量表-2 的敏感性较低(分别为 87.5%和 60.3%)。在个别领域,蒙特利尔认知评估对记忆和视觉空间损伤仍然敏感(分别为 91.9%和 87.8%),而 Mattis 痴呆评定量表-2 对执行功能损伤敏感(86.2%)。

结论

蒙特利尔认知评估和 Mattis 痴呆评定量表-2 各有优势。未来的工作应集中于为 PD 开发特定领域的认知筛查工具。© 2018 国际帕金森病和运动障碍协会。

相似文献

1
Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.MoCA 与 Mattis 痴呆评定量表-2 在帕金森病中的比较敏感性。
Mov Disord. 2019 Feb;34(2):285-291. doi: 10.1002/mds.27575. Epub 2018 Dec 10.
2
Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition.认知特征及常规认知测试在老年帕金森病、帕金森病痴呆、阿尔茨海默病及认知正常个体中的最佳截断值。
Psychogeriatrics. 2020 Jan;20(1):20-27. doi: 10.1111/psyg.12451. Epub 2019 Mar 25.
3
Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.帕金森病患者中蒙特利尔认知评估量表(MoCA-P)波斯语版本的有效性和可靠性。
Appl Neuropsychol Adult. 2020 Sep-Oct;27(5):431-439. doi: 10.1080/23279095.2019.1565762. Epub 2019 Mar 1.
4
Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised.帕金森病患者认知障碍的筛查:蒙特利尔认知评估量表巴西版和修订版Addenbrooke认知检查的诊断效度
Arq Neuropsiquiatr. 2015 Nov;73(11):929-33. doi: 10.1590/0004-282X20150156.
5
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease.帕金森病中简易精神状态检查表、蒙特利尔认知评估量表和痴呆评定量表-2评分之间的转换
Mov Disord. 2014 Dec;29(14):1809-15. doi: 10.1002/mds.26062. Epub 2014 Nov 7.
6
Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.蒙特利尔认知评估量表、简易精神状态检查和 SCOPA-Cog 在非痴呆帕金森病患者中的变化反应性。
Dement Geriatr Cogn Disord. 2019;47(4-6):187-197. doi: 10.1159/000496454. Epub 2019 Jul 17.
7
Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.马蒂斯痴呆评定量表评估卡巴拉汀治疗帕金森病痴呆疗效的效用
J Neurol. 2006 Sep;253(9):1154-9. doi: 10.1007/s00415-006-0175-2. Epub 2006 Sep 22.
8
Sensitivity and specificity of Addenbrooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease.简易智能精神状态检查、马特斯痴呆评定量表、额叶评估量表和简易精神状态检查在帕金森病患者痴呆诊断中的敏感性和特异性。
Parkinsonism Relat Disord. 2012 Jun;18(5):553-6. doi: 10.1016/j.parkreldis.2012.02.010. Epub 2012 Mar 8.
9
TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia.TMEM106B 对帕金森病和额颞叶痴呆认知的影响。
Ann Neurol. 2019 Jun;85(6):801-811. doi: 10.1002/ana.25486.
10
Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.帕金森病中轻度和重度神经认知障碍的筛查
Behav Neurol. 2015;2015:983606. doi: 10.1155/2015/983606. Epub 2015 May 19.

引用本文的文献

1
Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction.帕金森病的特征是维生素B6依赖的炎症性犬尿氨酸途径功能障碍。
NPJ Parkinsons Dis. 2025 Apr 26;11(1):96. doi: 10.1038/s41531-025-00964-7.
2
Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction.帕金森病的特征是维生素B6依赖的炎症性犬尿氨酸途径功能障碍。
Res Sq. 2024 Sep 26:rs.3.rs-4980210. doi: 10.21203/rs.3.rs-4980210/v1.
3
Validity of the MoCA as a cognitive screening tool in epilepsy: Are there implications for global care and research?MoCA 作为一种认知筛查工具在癫痫中的有效性:这对全球的护理和研究有何影响?
Epilepsia Open. 2024 Aug;9(4):1526-1537. doi: 10.1002/epi4.12991. Epub 2024 Jun 14.
4
Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra.多种生物标志物可提高路易体病和阿尔茨海默病谱的诊断准确性。
Ann Clin Transl Neurol. 2024 May;11(5):1197-1210. doi: 10.1002/acn3.52034. Epub 2024 Mar 4.
5
Neuropsychological assessment protocol in an ongoing randomized controlled trial on posterior subthalamic area vs. ventral intermediate nucleus deep brain stimulation for essential tremor.一项正在进行的关于丘脑底后区与腹中间核深部脑刺激治疗特发性震颤的随机对照试验中的神经心理学评估方案。
Front Neurol. 2023 Oct 30;14:1222592. doi: 10.3389/fneur.2023.1222592. eCollection 2023.
6
Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease.依折麦布联合低-中强度阿托伐他汀辅助阿司匹林治疗脑血管病的意义。
Comput Math Methods Med. 2022 Jul 18;2022:3369226. doi: 10.1155/2022/3369226. eCollection 2022.
7
Comparison of Montreal cognitive assessment and Mattis dementia rating scale in the preoperative evaluation of subthalamic stimulation in Parkinson's disease.蒙特利尔认知评估与马特斯痴呆评定量表在帕金森病患者丘脑底核刺激术前评估中的比较。
PLoS One. 2022 Apr 7;17(4):e0265314. doi: 10.1371/journal.pone.0265314. eCollection 2022.
8
Multiculturalism: A Challenge for Cognitive Screeners in Parkinson's Disease.多元文化主义:帕金森病认知筛查面临的挑战
Mov Disord Clin Pract. 2021 May 27;8(5):733-742. doi: 10.1002/mdc3.13240. eCollection 2021 Jul.
9
Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ.帕金森病患者的认知障碍与默认模式网络子系统连接和脑脊液 Aβ 有关。
Parkinsonism Relat Disord. 2021 Feb;83:71-78. doi: 10.1016/j.parkreldis.2021.01.002. Epub 2021 Jan 12.
10
White Matter Hyperintensities Related to Parkinson's Disease Executive Function.与帕金森病执行功能相关的白质高信号
Mov Disord Clin Pract. 2020 Apr 30;7(6):629-638. doi: 10.1002/mdc3.12956. eCollection 2020 Aug.

本文引用的文献

1
Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.用于帕金森病认知筛查的全球量表:批判与建议。
Mov Disord. 2018 Feb;33(2):208-218. doi: 10.1002/mds.27233. Epub 2017 Nov 23.
2
Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.利用临床基因评分预测帕金森病的认知功能:九个队列的纵向分析
Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16.
3
Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease.帕金森病中蒙特利尔认知评估各子部分的特定领域准确性。
Parkinsonism Relat Disord. 2017 May;38:31-34. doi: 10.1016/j.parkreldis.2017.02.008. Epub 2017 Feb 7.
4
Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with Parkinson's disease.韩国帕金森病患者中LRRK2 G2385R与认知功能障碍之间不存在关联。
J Clin Neurosci. 2017 Feb;36:108-113. doi: 10.1016/j.jocn.2016.10.013. Epub 2016 Nov 10.
5
The NINDS Parkinson's disease biomarkers program.美国国立神经疾病和中风研究所帕金森病生物标志物项目
Mov Disord. 2016 Jun;31(6):915-23. doi: 10.1002/mds.26438. Epub 2015 Oct 7.
6
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.GBA基因变异与帕金森病中一种独特的认知缺陷模式相关。
Mov Disord. 2016 Jan;31(1):95-102. doi: 10.1002/mds.26359. Epub 2015 Aug 21.
7
Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson's disease and normative data.马蒂斯痴呆评定量表在区分帕金森病轻度认知障碍及常模数据方面的临床效度
Dement Geriatr Cogn Disord. 2015;39(5-6):303-11. doi: 10.1159/000375365. Epub 2015 Mar 18.
8
Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson's disease.轻度认知障碍对帕金森病深部脑刺激手术预后的影响。
Parkinsonism Relat Disord. 2015 Mar;21(3):249-53. doi: 10.1016/j.parkreldis.2014.12.018. Epub 2014 Dec 31.
9
APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.帕金森病中的APOE、MAPT和SNCA基因与认知表现
JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.
10
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics.太平洋西北奥德尔卓越临床联盟中心:研究设计和基线队列特征。
J Parkinsons Dis. 2013;3(2):205-14. doi: 10.3233/JPD-130189.